We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Methylphenidate Raclopride Positron Emission Tomography (PET) Test - 11

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00015301
First Posted: April 18, 2001
Last Update Posted: February 24, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
New York MDRU
Information provided by:
National Institute on Drug Abuse (NIDA)
  Purpose
The purpose of this study is to evaluate PET methodology to study in vivo synaptic dopamine release.

Condition Intervention Phase
Cocaine-Related Disorders Substance-Related Disorders Drug: Methylphenidate Phase 4

Study Type: Interventional
Study Design: Masking: Double
Primary Purpose: Diagnostic
Official Title: Methylphenidate Raclopride PET Test

Resource links provided by NLM:


Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:
  • Dopamine receptor availability

Estimated Enrollment: 0
Actual Study Start Date: December 2003
Study Completion Date: August 2005
Primary Completion Date: June 2005 (Final data collection date for primary outcome measure)
Detailed Description:
The objective of this study is to evaluate PET methodology to study in vivo synaptic dopamine release.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Healthy normals

Exclusion Criteria:

History of head trauma or loss of consciousness. Significant medical history. History of seizures.

  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00015301


Locations
United States, New York
New York MDRU
New York, New York, United States, 10010
Sponsors and Collaborators
National Institute on Drug Abuse (NIDA)
New York MDRU
Investigators
Principal Investigator: John Rotrosen, M.D. New York MDRU
  More Information

ClinicalTrials.gov Identifier: NCT00015301     History of Changes
Other Study ID Numbers: NIDA-5-0013-11
Y01-5-0013-11
First Submitted: April 18, 2001
First Posted: April 18, 2001
Last Update Posted: February 24, 2017
Last Verified: December 2002

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Disease
Substance-Related Disorders
Cocaine-Related Disorders
Pathologic Processes
Chemically-Induced Disorders
Mental Disorders
Methylphenidate
Raclopride
Central Nervous System Stimulants
Physiological Effects of Drugs
Dopamine Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Dopamine Agents
Neurotransmitter Agents
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants
Psychotropic Drugs
Dopamine Antagonists